RNA-seq profiling of A549 and HCT116 human cancer cell lines

Rewiring of metabolism in cancer cells induced by oncogenic KRAS involves both glucose and glutamine utilization sustaining enhanced, unrestricted growth. The development of effective anti-cancer treatments targeting metabolism may be facilitated by the identification and rational combined targeting of metabolic pathways. By applying the Illumina next-generation sequencing technology, we analyzed the transcriptome profile of KRAS-mutant A549 lung cancer and HCT116 colon cancer cell lines before and after combined treatment with the glutaminase inhibitor CB-839 and the PI3K/aldolase inhibitor NVP-BKM120. The gene expression profiles were correlated with the metabolomic profiles obtained for the two cell lines under the same treatment condition.